Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours Β· Estimated delivery Aug 25 - Aug 30
Pair it with expert guidancelike OrderlyMeds GLP-1 treatments, nutrition, or fitness plansto support your health goals
At 12 months, the on-medication MDS-UPDRS Part III score was 14.9 in the lixisenatide group versus 18.8 in the placebo group, a between-group difference of 3.08 points (P = 0.007) [3]
The company incurred $33 million of restructuring costs in Q1, primarily consisting of the write-downs related to its compounded GLP-1 supply chain "that now faces risk of obsolescence," Okupe said during the call
This randomized phase 2a #ClinicalTrial demonstrates that TPN171H, a potent and selective PDE5 inhibitor, significantly reduces pulmonary vascular resistance and improves acute hemodynamics in patients with #PulmonaryArterialHypertension (PAH), establishing it as a promising and well-tolerated oral therapeutic candidate for managing PAH
US$ 21.62
US$ 22.76
US$ 25.12
US$ 20.20
US$ 25.73
US$ 29.76
US$ 28.10
